Sonnet BioTherapeutics unveils ADC Platform with promising preclinical results and partnership opportunities

CAR-T Digest - August 2020

19 Feb 2025: Sonnet BioTherapeutics unveils ADC Platform with promising preclinical results and partnership opportunities

Sonnet BioTherapeutics announced its ADC platform, leveraging its FHAB domain for flexible payload capacity and controllable drug-antibody ratios (DAR)
The SON-5010 ADC construct showed similar efficacy to Kadcyla and trastuzumab-MMAE in preclinical studies for HER2+ cancers
The platform offers structural integrity, tumor targeting, interchangeable toxin payloads, and flexible conjugation sites
SON-5010 demonstrated tumor reduction activity in vivo with no detectable toxicity, highlighting its potential clinical application
Sonnet aims to secure discovery partnerships and expand its intellectual property for developing novel ADC drug candidates